By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Radiologists, like their counterparts in other nations, are essential to the provision of high-quality healthcare on a regular basis. Japan is noted for having the world’s longest life expectancy, and life spans have increased recently. With 2.6 deaths per 1000 people, Japan has the lowest infant mortality rate among the G8 nations.
The healthcare system in Japan has a variety of features, including checkup programes that allow for early sickness detection and universal health insurance coverage. JFMDA firmly believes that the foundation of these traits is the widespread adoption of top-tier Japanese diagnostic and therapy technology.
One area of cooperation with the Japanese government is the medical sector, and healthcare professionals offer high-quality medical care to individuals not only in Japan but also in many other nations across the world.
The Japan Medical Imaging market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The Israeli company TechsoMed Ltd., which has a Japanese affiliate, creates ultrasound-based image processing software for tissue damage monitoring and control in multiple therapeutic applications.
The system from TechsoMed is intended for real-time image processing in numerous therapeutic settings, including oncology, cardiology, and pain management (radiofrequency neurotomy).
With the help of AI algorithms, the BioTrace platform can follow each individual biological tissue’s reaction to TA and display the formation of a tissue damage map.
The damage map shows the complete amount of the damage after CT imaging therapy and can help to improve treatment accuracy, reduce damage to healthy tissue, and maximise target tissue ablation.
The system is in an advanced development stage as a consequence of preliminary clinical validation that was carried out successfully in the University of Tokyo Hospital, Japan, with over 50 human cases demonstrating consistent high match findings compared to 24 hours post-procedure CECT (Contrast-Enhanced Computed Tomography).
The FDA is likely to approve TechsoMed’s first product, BioTrace IO, which is primarily intended for use in liver tumour ablation treatments and is currently undergoing clinical validation in a multi-center trial in the USA. Additionally, the business is working with Japan’s Juntendo University to further clinically evaluate the BioTrace IO product.
